251 related articles for article (PubMed ID: 9428495)
1. Elevated levels of telomerase activity in malignant pheochromocytoma.
Kubota Y; Nakada T; Sasagawa I; Yanai H; Itoh K
Cancer; 1998 Jan; 82(1):176-9. PubMed ID: 9428495
[TBL] [Abstract][Full Text] [Related]
2. KI-67 AND hTERT expression can aid in the distinction between malignant and benign pheochromocytoma and paraganglioma.
Elder EE; Xu D; Höög A; Enberg U; Hou M; Pisa P; Gruber A; Larsson C; Bäckdahl M
Mod Pathol; 2003 Mar; 16(3):246-55. PubMed ID: 12640105
[TBL] [Abstract][Full Text] [Related]
3. Predicting metastasis of pheochromocytomas using DNA flow cytometry and immunohistochemical markers of cell proliferation: A positive correlation between MIB-1 staining and malignant tumor behavior.
Brown HM; Komorowski RA; Wilson SD; Demeure MJ; Zhu YR
Cancer; 1999 Oct; 86(8):1583-9. PubMed ID: 10526289
[TBL] [Abstract][Full Text] [Related]
4. Telomerase activity in benign and malignant adrenal tumors.
Bamberger CM; Else T; Bamberger AM; Frilling A; Beil FU; Allolio B; Schulte HM
Exp Clin Endocrinol Diabetes; 1999; 107(4):272-5. PubMed ID: 10433067
[TBL] [Abstract][Full Text] [Related]
5. Clinical utility of telomerase for the diagnosis of malignant well-differentiated endocrine tumours.
Vezzosi D; Bouisson M; Escourrou G; Laurell H; Selves J; Seguin P; Pradayrol L; Caron P; Buscail L
Clin Endocrinol (Oxf); 2006 Jan; 64(1):63-7. PubMed ID: 16402930
[TBL] [Abstract][Full Text] [Related]
6. Telomerase activity as prognostic factor in gastrointestinal stromal tumors of the stomach.
Kawai J; Kodera Y; Fujiwara M; Kasai Y; Nagasaka T; Koike M; Hibi K; Ito K; Akiyama S; Nakao A
Hepatogastroenterology; 2005; 52(63):959-64. PubMed ID: 15966241
[TBL] [Abstract][Full Text] [Related]
7. [Pheochromocytoma--pathohistologic and immunohistochemical aspects].
Tatić S; Havelka M; Paunović I; Bozić V; Diklic A; Brasanac D; Janković R; Jancić-Zguricas M
Srp Arh Celok Lek; 2002 Jul; 130 Suppl 2():7-13. PubMed ID: 12584991
[TBL] [Abstract][Full Text] [Related]
8. Expression profile of the telomeric complex discriminates between benign and malignant pheochromocytoma.
Boltze C; Mundschenk J; Unger N; Schneider-Stock R; Peters B; Mawrin C; Hoang-Vu C; Roessner A; Lehnert H
J Clin Endocrinol Metab; 2003 Sep; 88(9):4280-6. PubMed ID: 12970299
[TBL] [Abstract][Full Text] [Related]
9. Remarkably suppressed manganese superoxide dismutase activity in malignant pheochromocytoma.
Nakada T; Kubota Y; Sasagawa I; Yagisawa T; Watanabe M; Ishigooka M
J Urol; 1995 Jun; 153(6):1787-90. PubMed ID: 7752317
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA profiling of benign and malignant pheochromocytomas identifies novel diagnostic and therapeutic targets.
Meyer-Rochow GY; Jackson NE; Conaglen JV; Whittle DE; Kunnimalaiyaan M; Chen H; Westin G; Sandgren J; Stålberg P; Khanafshar E; Shibru D; Duh QY; Clark OH; Kebebew E; Gill AJ; Clifton-Bligh R; Robinson BG; Benn DE; Sidhu SB
Endocr Relat Cancer; 2010 Sep; 17(3):835-46. PubMed ID: 20621999
[TBL] [Abstract][Full Text] [Related]
11. Should pheochromocytoma size influence surgical approach? A comparison of 90 malignant and 60 benign pheochromocytomas.
Shen WT; Sturgeon C; Clark OH; Duh QY; Kebebew E
Surgery; 2004 Dec; 136(6):1129-37. PubMed ID: 15657566
[TBL] [Abstract][Full Text] [Related]
12. [The significance of Ki-67 antigen expression in the distinction between benign and malignant pheochromocytomas].
Feng C; Li HZ; Yan WG; Gao JG; Xu WF; Luo YF; Cao JL
Zhonghua Wai Ke Za Zhi; 2007 Dec; 45(24):1697-700. PubMed ID: 18476530
[TBL] [Abstract][Full Text] [Related]
13. Flow cytometric DNA analysis for the determination of malignant potential in adrenal and extra-adrenal pheochromocytomas or paragangliomas.
Pang LC; Tsao KC
Arch Pathol Lab Med; 1993 Nov; 117(11):1142-7. PubMed ID: 8239937
[TBL] [Abstract][Full Text] [Related]
14. Candidate genes associated with malignant pheochromocytomas by genome-wide expression profiling.
Suh I; Shibru D; Eisenhofer G; Pacak K; Duh QY; Clark OH; Kebebew E
Ann Surg; 2009 Dec; 250(6):983-90. PubMed ID: 19661783
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic management of benign and malignant pheochromocytoma.
Scholz T; Schulz C; Klose S; Lehnert H
Exp Clin Endocrinol Diabetes; 2007 Mar; 115(3):155-9. PubMed ID: 17427102
[TBL] [Abstract][Full Text] [Related]
16. Stathmin as a marker for malignancy in pheochromocytomas.
Björklund P; Cupisti K; Fryknäs M; Isaksson A; Willenberg HS; Akerström G; Hellman P; Westin G
Exp Clin Endocrinol Diabetes; 2010 Jan; 118(1):27-30. PubMed ID: 19449284
[TBL] [Abstract][Full Text] [Related]
17. Differential expression and processing of secretogranin II in relation to the status of pheochromocytoma: implications for the production of the tumoral marker EM66.
Guillemot J; Thouënnon E; Guérin M; Vallet-Erdtmann V; Ravni A; Montéro-Hadjadje M; Lefebvre H; Klein M; Muresan M; Seidah NG; Anouar Y; Yon L
J Mol Endocrinol; 2012 Apr; 48(2):115-27. PubMed ID: 22217803
[TBL] [Abstract][Full Text] [Related]
18. The role of immunohistochemistry in histopathological diagnostics of clinically "silent" incidentally detected adrenal masses.
Babinska A; Sworczak K; Wisniewski P; Nałecz A; Jaskiewicz K
Exp Clin Endocrinol Diabetes; 2008 Apr; 116(4):246-51. PubMed ID: 18393131
[TBL] [Abstract][Full Text] [Related]
19. Microarray analysis reveals differential expression of benign and malignant pheochromocytoma.
Waldmann J; Fendrich V; Holler J; Buchholz M; Heinmöller E; Langer P; Ramaswamy A; Samans B; Walz MK; Rothmund M; Bartsch DK; Slater EP
Endocr Relat Cancer; 2010 Sep; 17(3):743-56. PubMed ID: 20562231
[TBL] [Abstract][Full Text] [Related]
20. Comparative analysis of K-ras point mutation, telomerase activity, and p53 overexpression in pancreatic tumours.
Uemura K; Hiyama E; Murakami Y; Kanehiro T; Ohge H; Sueda T; Yokoyama T
Oncol Rep; 2003; 10(2):277-83. PubMed ID: 12579258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
